Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPoolbeg Pharma Regulatory News (POLB)

Share Price Information for Poolbeg Pharma (POLB)

Share Price is delayed by 15 minutes
Get Live Data
8.25    -0.25 (-2.94%)
Bid:
8.00
Ask:
8.50
Spread: 0.50 (6.25%)
Market Cap: £58.17m
POLB Live PriceLast checked at - London Stock Exchange

Intraday Poolbeg Pharma Share Chart

TR-1

23 Jul 2021 13:26

RNS Number : 3269G
Poolbeg Pharma PLC
23 July 2021
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

Poolbeg Pharma PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii:

3. Details of person subject to the notification obligationiv

Name

Schroders PLC

City and country of registered office (if applicable)

London, United Kingdom

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

21/07/2021

6. Date on which issuer notified (DD/MM/YYYY):

22/07/2021

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuervii

Resulting situation on the date on which threshold was crossed or reached

5.128388%

N/A

5.128388%

25,641,941

Position of previous notification (if

applicable)

N/A

N/A

N/A

 

 

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

Direct

(DTR5.1)

Indirect

(DTR5.2.1)

GB00BKPG7Z60

25,641,941

5.128388%

SUBTOTAL 8. A

25,641,941

5.128388%

 

 

B 1: Financial Instruments according to DTR5.3.1R (1) (a)

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to DTR5.3.1R (1) (b)

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

 

 

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

X

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

Schroders PLC

Schroder Administration Limited

Schroder Wealth Holdings Limited

Schroder & Co. Limited

Schroders plc

Schroder Administration Limited

Schroder International Holdings Limited

Schroder Investment Management Limited

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

22/07/2021

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLDKNBBBBKDQOB
Date   Source Headline
9th Jan 20254:28 pmRNSForm 8.5- Poolbeg Pharma PLC
9th Jan 202511:01 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
9th Jan 20258:53 amRNSForm 8.5 (EPT/NON-RI)
9th Jan 20257:00 amRNSHolding(s) in Company
8th Jan 20253:56 pmRNSForm 8.5 (EPT/NON-RI) - Poolbeg Pharma PLC
8th Jan 20253:53 pmRNSForm 8 (OPD) - Poolbeg Pharma plc
8th Jan 202510:51 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
8th Jan 20259:44 amRNSForm 8.5 (EPT/NON-RI)
7th Jan 202510:54 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
7th Jan 202510:48 amRNSForm 8.5 (EPT/NON-RI)
7th Jan 20257:00 amRNSUpdate Potential Combination of Poolbeg & HOOKIPA
6th Jan 202510:27 amRNSForm 8.5 (EPT/NON-RI)
6th Jan 202510:19 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
3rd Jan 202511:40 amRNSForm 8.5 (EPT/NON-RI)
3rd Jan 202511:34 amGNWForm 8.5 (EPT/RI) - Poolbeg Pharma Plc
2nd Jan 20257:00 amRNSCombination of Poolbeg and HOOKIPA Pharma Inc.
20th Nov 20247:00 amRNSPOLB 001 Patent Granted in United States
18th Sep 20247:00 amRNSInterim results for the six months to 30 June 2024
12th Aug 20241:28 pmRNSHolding(s) in Company
26th Jul 20247:00 amRNSVoluntary Delisting from OTCQB Market
10th Jul 20247:00 amRNSNotification of Major Holdings
2nd Jul 20247:00 amRNSChange of Registered Address
17th Jun 20248:38 amRNSResult of AGM
9th May 20247:00 amRNSAnnual Report & AGM Notice
1st May 20247:00 amRNSSignificant POLB 001 Patent Granted in USA
30th Apr 20247:02 amRNSAppointment of Joint Broker
30th Apr 20247:01 amRNSOption Agreement to Acquire Orphan Drug Candidate
30th Apr 20247:00 amRNSResults for the year ended 31 December 2023
29th Apr 20247:00 amRNSTR-1: Notification of major holdings
22nd Feb 20247:00 amRNSDirector/PDMR Shareholding
19th Feb 20241:42 pmRNSDirector Share Purchase
15th Feb 20247:00 amRNSBoard Role Change and Launch of EIP
17th Jan 20247:00 amRNSFurther data shows POLB001 potential in cancer CRS
20th Dec 20237:00 amRNSRSV AI Drug Candidate Analysis Update
11th Dec 20237:00 amRNSPOLB 001 Data Presented at ASH
30th Nov 20237:00 amRNSDirectorate Change
21st Nov 20237:00 amRNSImmunomodulator II patent granted in Japan
16th Nov 20237:00 amRNSPOLB 001 LPS Trial Data to be Presented at IUIS
9th Nov 20237:00 amRNSFormer Amryt Pharma Leadership Team join Poolbeg
3rd Nov 20237:05 amRNSPOLB001 Data to be Presented at ASH Annual Meeting
1st Nov 20237:00 amRNSPOLB 001 Oncology Programme Update Meeting
26th Oct 20237:00 amRNSSAB Endorses Influenza Drug Targets
17th Oct 20237:00 amRNSPoolbeg Partners with a Nasdaq-Listed Biopharma
29th Sep 20237:00 amRNSFavourable Conclusion of Patent Opposition
20th Sep 20237:00 amRNSImmunomodulator I Patent Portfolio Strengthened
19th Sep 20237:00 amRNSImmunomodulator I Patent Opposition Withdrawal
13th Sep 20237:00 amRNSInterim results for the six months to 30 June 2023
29th Jun 20237:00 amRNSAI led programme identifies influenza drug targets
22nd Jun 20237:00 amRNSOral Vaccine Programme Moves Forward
24th May 20237:00 amRNSBoard Appointment

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.